Novavax, Inc. Stock price Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 850M | Sales 2025 * | 929M | Capitalization | 669M |
---|---|---|---|---|---|
Net income 2024 * | -90M | Net income 2025 * | - | EV / Sales 2024 * | 0.19 x |
Net cash position 2024 * | 510M | Net cash position 2025 * | 482M | EV / Sales 2025 * | 0.2 x |
P/E ratio 2024 * |
-6
x | P/E ratio 2025 * |
46.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.33% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |